Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (October 2024)
20 slides from Imagion Biosystems's investor presentation, Oct 10, 2024
Slide 1: A Breakthrough in Cancer Detection
Imagion Biosystems Limited ASX:IBX A Breakthrough in Cancer Detection Molecular Magnetic Resonance Imaging 1 Investor Deck – ASX:IBX Copyright October 2024 | ImagionBiosystems.com
Slide 2: Imagion Biosystems - MagSense Technology Overview
Imagion Biosystems - MagSense® Technology Overview 2 Investor Deck – ASX:IBX Copyright October 2024 | ImagionBiosystems.com
Slide 3: Imagion Biosystems Overview
Imagion Biosystems Overview A clinical stage biotechnology company developing magnetic nanoparticle-based imaging and drug delivery technologies Molecular Imaging Lead Product Targeted nanoparticles have the potential to A Phase 1 study for the detection of nodal improve cancer detection compared to
Slide 4: An Unmet Need in Cancer Diagnosis
An Unmet Need in Cancer Diagnosis Screening Imaging Biopsy Conventional blood- Current imaging To confirm if a lesion is malignant, based tests, like PSA or methods can be biopsies are taken which may be painful CA125, indicate risk of used to identify a and cause patient complications. cancer but a
Slide 5: Imagion 2.0 - Investor Summary
Imagion 2.0 - Investor Summary Corporate and Operational Restructuring Completed Key Clinical Milestone Significantly Reduced Operating Strong Pipeline Achieved Costs • Phase 1 study in 13 • MagSense® HER2 being • Eliminated costs of R&D and HER2+ breast cancer readied for IND application for Manufa
Slide 6: New Leadership Team
0.1 2.5 0.09 Share price (A$) New Leadership Team 0.08 2 Millions 0.07 0.06 1.5 0.05 0.04 1 0.03 0.02 0.5 Robert Proulx Ward Detwiler Executive Chairman Chief Business Officer 0.01 Robert is a veteran executive of the life Experienced early-stage technology science and medical device sectors and has
Slide 7: MagSense Technology
MagSense® Technology A Breakthrough 7 Investor Deck – ASX:IBX Copyright October 2024 | ImagionBiosystems.com
Slide 8: IBX Enables Molecular Imaging
IBX Enables Molecular Imaging Conventional Imaging MagSense®Imaging Images provide anatomical context but are Molecularly targeted imaging agents produce a not specific and can only identify a region distinct image pattern indicating the presence of of interest. a tumor. 8 Investor Deck – ASX:IBX Co
Slide 9: MagSense Molecular Imaging
MagSense Molecular Imaging ® MagSense® technology aims to transform how medical imaging can detect and diagnose cancer MRI-based Specific Safer Earlier Platform Detection Detection Technology Imaging agents work Targeted imaging agents Does not require use of Would enable earlier Fits with existing
Slide 10: How IBX molecular MRI works
MagSense® nanoparticles enable molecular imaging by producing an identifiable change in image contrast How IBX molecular when cancer cells are present MRI works • A targeting moiety (e.g. antibody or peptide) Pre-Dose Post-Dose directs the nanoparticles to the target tissue to ensure cancer specific
Slide 11: $3-4B Market Opportunity
$3-4B Market Opportunity MagSense® Use Cases Detection of Nodal Metastases in Primary Tumor Detection Early Detection of Ovarian Cancer HER2+ Breast Cancer in Prostate Cancer Following primary tumor diagnosis Following primary tumor diagnosis Following elevated PSA blood test, the determine if the c
Slide 12: Phase 1 Study – Completed
Phase 1 Study – Completed Detection of Nodal Metastases in HER2+ Breast Cancer • A Phase 1 Study with 13 HER2+ Breast Cancer patients from 4 sites in Australia. IBI010103 • Imaging agent was safe and well tolerated in all 13 patients with no AE/SAEs reported related to the imaging agent. • Blinded r
Slide 13: MagSense will Improve Radiological Review
MagSense® will Improve Radiological Review • Radiological assessment is often subjective, with significant inter-operator Post-Contrast differences in interpretation. • Automated software for detection and segmentation of MagSense® tagged cells will enable: • Faster, more accurate reads • Longitudin
Slide 14: Rationale for MagSense Imaging Agents
Rationale for MagSense® Imaging Agents Large addressable markets ($B’s), Expanding access, and Improving outcomes 1. There are >50,000 MRI scanners available globally (5x as many as PET imaging systems). 2. MagSense® imaging agents have long shelf life and can be stored and supplied by the hospital
Slide 15: Path to Growth and Key Value Catalysts
Path to Growth and Key Value Catalysts Clinical Development Plan and Key Milestones Near-Term Completed 2024 - 2025 Funding Needs HER2+ IND File IND and initiate Breast Phase 1 Phase 2 Phase 3 Phase 2 study for HER2 Cancer Dose and Image Protocol Optimization imaging agent IND Ovarian Cancer Pre-Cli
Slide 16: Investor Rationale
Investor Rationale 16 Investor Deck – ASX:IBX Copyright October 2024 | ImagionBiosystems.com
Slide 17: Focus on Strategic Partnering
Sources: (1) JAMA Oncology. 2022. Medicare Payment Advisory Commission (MedPAC) and Centers for Medicare and Medicaid Services (CMS). Mordor Intelligence. Global Focus on Strategic Partnering Contrast Media Market 1. Use of contrast media is well established across medical imaging technologies with
Slide 18: Comparable Transactions
Comparable Transactions Acquirer Target Value AUD Year Notes Strategic investment. Part of $70M $18M 2024 AUD financing transaction. $35M revenue at time of transaction. $310M 2024 Breast cancer Imuno-oncology agent. Acquired $1.6B 2018 following successful Phase 3. All stock acquisition. Estimated
Slide 19: Investment Proposition
Investment Proposition 1. MagSense® imaging agents have a high probability of receiving regulatory approval - nearly 100% of contrast media submitted to the FDA are approved. Example Probability of Success at Stage 2. Progressing through each stage in clinical development IND Enabling 24% increases
Slide 20: info@imagionbio.com | ASX:IBX
info@imagionbio.com | ASX:IBX 20 Investor Deck – ASX:IBX Copyright October 2024 | ImagionBiosystems.com
Imagion Biosystems — Investor Presentation (October 2024) on 6ix